These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 34336112)

  • 1. Association between PCSK9 Levels and Markers of Inflammation, Oxidative Stress, and Endothelial Dysfunction in a Population of Nondialysis Chronic Kidney Disease Patients.
    Dounousi E; Tellis C; Pavlakou P; Duni A; Liakopoulos V; Mark PB; Papagianni A; Tselepis AD
    Oxid Med Cell Longev; 2021; 2021():6677012. PubMed ID: 34336112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma PCSK9 concentrations during the course of nondiabetic chronic kidney disease: Relationship with glomerular filtration rate and lipid metabolism.
    Morena M; Le May C; Chenine L; Arnaud L; Dupuy AM; Pichelin M; Leray-Moragues H; Chalabi L; Canaud B; Cristol JP; Cariou B
    J Clin Lipidol; 2017; 11(1):87-93. PubMed ID: 28391915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An in-depth analysis shows a hidden atherogenic lipoprotein profile in non-diabetic chronic kidney disease patients.
    Bermudez-Lopez M; Forne C; Amigo N; Bozic M; Arroyo D; Bretones T; Alonso N; Cambray S; Del Pino MD; Mauricio D; Gorriz JL; Fernandez E; Valdivielso JM
    Expert Opin Ther Targets; 2019 Jul; 23(7):619-630. PubMed ID: 31100024
    [No Abstract]   [Full Text] [Related]  

  • 4. PCSK9 in chronic kidney disease.
    Pavlakou P; Liberopoulos E; Dounousi E; Elisaf M
    Int Urol Nephrol; 2017 Jun; 49(6):1015-1024. PubMed ID: 28084558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemia.
    Shrestha P; van de Sluis B; Dullaart RPF; van den Born J
    Cell Signal; 2019 Mar; 55():53-64. PubMed ID: 30550765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of cardiovascular events and progression to end-stage renal disease in patients with dyslipidemia and chronic kidney disease from the North-Eastern area of Romania.
    Vlad CE; Foia L; Pavel-Tanasa M; Toma V; Florea L; Voroneanu L; Apetrii M; Dodi G; Covic A
    Int Urol Nephrol; 2022 Mar; 54(3):647-659. PubMed ID: 34224064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between circulating proprotein convertase subtilisin/kexin type 9 levels and prognosis in patients with severe chronic kidney disease.
    Rasmussen LD; Bøttcher M; Ivarsen P; Jørgensen HS; Nyegaard M; Buttenschøn H; Gustafsen C; Glerup S; Bøtker HE; Svensson M; Winther S
    Nephrol Dial Transplant; 2020 Apr; 35(4):632-639. PubMed ID: 30137516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia.
    Afanasieva OI; Ezhov MV; Razova OA; Afanasieva MI; Utkina EA; Pokrovsky SN
    Atherosclerosis; 2018 Oct; 277():477-482. PubMed ID: 30270088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arylesterase activity but not PCSK9 levels is associated with chronic kidney disease in type 2 diabetes.
    Didas N; Thitisopee W; Porntadavity S; Jeenduang N
    Int Urol Nephrol; 2020 Sep; 52(9):1725-1732. PubMed ID: 32661629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma Levels of Proprotein Convertase Subtilisin/Kexin Type 9 Are Elevated in Patients With Peripheral Artery Disease and Associated With Metabolic Disorders and Dysfunction in Circulating Progenitor Cells.
    Chao TH; Chen IC; Li YH; Lee PT; Tseng SY
    J Am Heart Assoc; 2016 May; 5(5):. PubMed ID: 27207972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) is Independently Associated with Insulin Resistance, Triglycerides, Lipoprotein(a) Levels but not Low-Density Lipoprotein Cholesterol Levels in a General Population.
    Hamamura H; Adachi H; Enomoto M; Fukami A; Nakamura S; Nohara Y; Morikawa N; Sakaue A; Toyomasu K; Yamamoto M; Fukumoto Y
    J Atheroscler Thromb; 2021 Apr; 28(4):329-337. PubMed ID: 32624555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic kidney disease on hemodialysis is associated with decreased serum PCSK9 levels.
    Abujrad H; Mayne J; Ruzicka M; Cousins M; Raymond A; Cheesman J; Taljaard M; Sorisky A; Burns K; Ooi TC
    Atherosclerosis; 2014 Mar; 233(1):123-9. PubMed ID: 24529132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypercholesterolemia in Progressive Renal Failure Is Associated with Changes in Hepatic Heparan Sulfate - PCSK9 Interaction.
    Shrestha P; Adepu S; Vivès RR; Masri RE; Klooster A; Kaptein F; Dam W; Bakker SJL; van Goor H; van de Sluis B; van den Born J
    J Am Soc Nephrol; 2021 Jun; 32(6):1371-1388. PubMed ID: 33758009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid Management in Chronic Kidney Disease: Systematic Review of PCSK9 Targeting.
    Zheng-Lin B; Ortiz A
    Drugs; 2018 Feb; 78(2):215-229. PubMed ID: 29299849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PCSK9 and Cardiovascular Disease in Individuals with Moderately Decreased Kidney Function.
    Kheirkhah A; Lamina C; Kollerits B; Schachtl-Riess JF; Schultheiss UT; Forer L; Sekula P; Kotsis F; Eckardt KU; Kronenberg F;
    Clin J Am Soc Nephrol; 2022 Jun; 17(6):809-818. PubMed ID: 35387881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic Effect of Inflammatory Cytokines and Body Adiposity on Insulin Resistance and Endothelial Markers in Patients With Stages 3-5 Chronic Kidney Disease.
    Barreto Silva MI; Klein MRST; Cardoso ÉS; Costa MS; Martins CJM; Bregman R
    J Ren Nutr; 2020 Jan; 30(1):36-45. PubMed ID: 30956091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma proprotein convertase subtilisin/kexin type 9 is associated with Lp(a) in type 2 diabetic patients.
    Nekaies Y; Baudin B; Kelbousi S; Sakly M; Attia N
    J Diabetes Complications; 2015; 29(8):1165-70. PubMed ID: 26412029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PCSK9 in diabetic kidney disease.
    Elewa U; Fernández-Fernández B; Mahillo-Fernández I; Martin-Cleary C; Sanz AB; Sanchez-Niño MD; Ortiz A
    Eur J Clin Invest; 2016 Sep; 46(9):779-86. PubMed ID: 27438893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk.
    Arsenault BJ; Petrides F; Tabet F; Bao W; Hovingh GK; Boekholdt SM; Ramin-Mangata S; Meilhac O; DeMicco D; Rye KA; Waters DD; Kastelein JJP; Barter P; Lambert G
    J Clin Lipidol; 2018; 12(1):130-136. PubMed ID: 29103916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.